Continuing medical educationPsoriasis and comorbid diseases: Epidemiology
Key words
Abbreviations used
Cited by (0)
Supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K24AR064310 (Dr Gelfand), T32AR00746532 (Ms Grewal), K23AR063764 (Dr Ogdie), and K23AR068433 (Dr Takeshita), a Dermatology Foundation Career Development Award (Dr Takeshita), the Intramural Research Program at the National Institutes of Health grant ZIAHL006193-02 (Mehta), and a National Institute for Health Research Clinician Scientist Fellowship (grant NIHR/CS/010/014 to Dr Langan). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the UK Department of Health.
Dr Takeshita has received a research grant (to the Trustees of the University of Pennsylvania) from Pfizer Inc and payment for continuing medical education work related to psoriasis. Dr Mehta is a full-time employee of the US Government. Dr Ogdie receives research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc (to the Trustees of the University of Pennsylvania and GRAPPA), and has served as a consultant for Novartis, receiving honoraria. Dr Van Voorhees has served as a consultant for AbbVie, Amgen, Aqua, AstraZeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria; received a research grant from AbbVie; and has other relationship with Merck. Dr Gelfand has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis. Dr Gelfand is a co–patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. No other potential conflicts of interest were declared by the authors.
Date of release: March 2017
Expiration date: March 2020